Search results for "germline pathogenic variant"

showing 4 items of 4 documents

Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/…

2020

Recent advances in the detection of germline pathogenic variants (PVs) in BRCA1/2 genes have allowed a deeper understanding of the BRCA-related cancer risk. Several studies showed a significant heterogeneity in the prevalence of PVs across different populations. Because little is known about this in the Sicilian population, our study was aimed at investigating the prevalence and geographic distribution of inherited BRCA1/2 PVs in families from this specific geographical area of Southern Italy. We retrospectively collected and analyzed all clinical information of 1346 hereditary breast and/or ovarian cancer patients genetically tested for germline BRCA1/2 PVs at University Hospital Policlini…

0301 basic medicineCancer Researchendocrine system diseasesPopulationSicilian populationBiologylcsh:RC254-282hereditary breast and ovarian cancerArticleGermlinefounder variantsgenetic testing03 medical and health sciences0302 clinical medicineBreast cancerbreast cancermedicineskin and connective tissue diseaseseducationGeneGenetic testinggermline pathogenic varianteducation.field_of_studyfounder variantmedicine.diagnostic_testGenetic heterogeneitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBRCA1BRCA2language.human_language<i>BRCA1</i>030104 developmental biologyovarian cancerOncology030220 oncology & carcinogenesiscardiovascular systemlanguagegermline pathogenic variantsOvarian cancerSicilian<i>BRCA2</i>Demography
researchProduct

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants i…

2020

Simple Summary Many bilateral breast cancer patients with increased hereditary susceptibility to breast cancer result negative for BRCA1 or BRCA2 pathogenic variants and, thus, need a further genetic testing through a broader gene panel. Some patients with negative test result for BRCA1/2 pathogenic variants may harbor pathogenic variants in other breast cancer susceptibility genes, including ATM, CHEK2, PALB2, PTEN, TP53. Of course, the use of a multi-gene panel provides clinicians more information through a single test. Therefore, we focused on potential clinical impact of a NGS-based multi-gene panel testing in bilateral breast cancer patients, in order to evaluate the utility of perform…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPTENSettore MED/06 - Oncologia MedicaPALB2<i>CHECK2</i><i>PTEN</i>lcsh:RC254-282GermlineArticle03 medical and health sciencesCHECK20302 clinical medicineGermline mutationBreast cancerbreast cancerInternal medicinemedicinePTENCancer Familyskin and connective tissue diseasesbilateral breast cancerCHEK2germline pathogenic variantbiologybusiness.industry<i>ATM</i>lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBRCA1BRCA2<i>BRCA1</i>030104 developmental biologyOncology030220 oncology & carcinogenesisATMPALB2biology.proteinmulti-gene panel testingRAD51C<i>PALB2</i>germline pathogenic variantsbusiness<i>BRCA2</i>Cancers
researchProduct

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

2020

Background: Several available data suggest the association between specific molecular subtypes and BRCA1/2 mutational status. Previous investigations showed the association between BRCA1/2 pathogenic variants (PVs) in specific genomic regions and phenotypic variations of cancer relative risk, while the role of PV type and location in determining the breast cancer (BC) phenotypic features remains still unclear. The aim of this research was to describe the germline BRCA1/2 PVs in triple-negative breast cancer (TNBC) versus luminal-like BC and their potential leverage on BC phenotype. Patients &amp; methods: We retrospectively collected and analyzed all clinical information of 531 patients wit…

0301 basic medicineOncologymedicine.medical_specialtygenetic testingGenotype phenotypeCorrelation03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerInternal medicinemedicineMutational statusskin and connective tissue diseasesTriple negativeTriple-negative breast cancerOriginal ResearchGenetic testinggermline pathogenic variantmedicine.diagnostic_testbusiness.industryBRCA1medicine.diseaseBRCA2030104 developmental biologyluminal-like breast cancerOncology030220 oncology & carcinogenesisCohorttriple-negative breast cancergermline pathogenic variantsbusinessTherapeutic Advances in Medical Oncology
researchProduct

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel …

2021

Background Hereditary breast cancer (BC), ovarian cancer (OC), and pancreatic cancer (PC) are the major BRCA-associated tumours. However, some BRCA1/2-wild-type (wt) patients with a strong personal and/or family history of cancer need a further genetic testing through a multi-gene panel containing other high- and moderate-risk susceptibility genes. Patients and methods Our study was aimed to assess if some BC, OC, or PC patients should be offered multi-gene panel testing, based on well-defined criteria concerning their personal and/or family history of cancer, such as earliness of cancer onset, occurrence of multiple tumours, or presence of at least two or more affected first-degree relativ…

OncologyCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaPALB2pancreatic cancerBreast NeoplasmsBreast cancerbreast cancerMUTYHInternal medicinePancreatic cancerMedicineHumansGenetic Predisposition to DiseaseGenetic TestingFamily historyCHEK2Original ResearchGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA1 ProteinCancermedicine.diseasePancreatic Neoplasmsovarian cancerOncologymulti-gene panel testingFemalegermline pathogenic variantsbusiness
researchProduct